Toxicology in the ICU - Part 1: General overview and approach to treatment

Chest

Volumn 140, Issue 3, 2011, Pages 795-806

  Levine, Michael ^a   Brooks, Daniel E ^a   Truitt, Carrie A ^a   Wolk, Brian J ^b   Boyer, Edward W ^b   Ruha, Anne Michelle ^a  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALCOHOL; ANTIHISTAMINIC AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CAFFEINE; CARISOPRODOL; CHLORAL HYDRATE; CLENBUTEROL; COCAINE; CYCLOBENZAPRINE; DEXTROPROPOXYPHENE; EDROPHONIUM; GLUCOSE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; NALOXONE; NEUROLEPTIC AGENT; ORGANOPHOSPHATE INSECTICIDE; PETHIDINE; PHYSOSTIGMINE; PSEUDOEPHEDRINE; THEOPHYLLINE; THIAMINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLPIDEM;

ANTICHOLINERGIC TOXIDROME; BLOATING; CHOLINERGIC TOXIDROME; CONSTIPATION; CRITICALLY ILL PATIENT; DETERIORATION; DIARRHEA; DRUG DOSE INCREASE; DRUG HALF LIFE; ENVENOMATION; HUMAN; INTENSIVE CARE UNIT; INTOXICATION; LABORATORY TEST; MEDICAL LITERATURE; NEUROMONITORING; NONHUMAN; OPIOID TOXIDROME; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PUBLICATION; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEDATIVE HYPNOTIC TOXIDROME; SYMPATHOMIMETIC TOXIDROME; TOXICOLOGY; VOMITING; WERNICKE ENCEPHALOPATHY;

EID: 80052664752     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2548     Document Type: Review

References (142)

1. Kaufman DM, Hegyi T, Duberstein JL. Heroin intoxication in adolescents. Pediatrics. 1972;50(5):746-753.
2. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130(7):584-590. (Pubitemid 29169387)
3. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med. 1991;20(3):246-252.
4. Buck ML, Blumer JL. Opioids and other analgesics. Adverse effects in the intensive care unit. Crit Care Clin. 1991;7(3):615-637.
5. Wald PH, Weisman RS, Goldfrank L. Opioids. Top Emerg Med. 1985;7(3):9-17.
6. Clark RF, Wei EM, Anderson PO. Meperidine: therapeutic use and toxicity. J Emerg Med. 1995;13(6):797-802.
7. Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol. JAMA. 1997;278(20):1661.
8. Stork CM, Redd JT, Fine K, Hoffman RS. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate - a case report. J Toxicol Clin Toxicol. 1995;33(2):179-183.
9. Whitcomb DC, Gilliam FR III, Starmer CF, Grant AO. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine. J Clin Invest. 1989;84(5):1629-1636. (Pubitemid 19272252)
10. Ghoneim MM, Dhanaraj J, Choi WW. Comparison of four opioid analgesics as supplements to nitrous oxide anesthesia. Anesth Analg. 1984;63(4):405-412. (Pubitemid 14172610)
11. Krantz MJ, Mehler PS. QTc prolongation: methadone's efficacy-safety paradox. Lancet. 2006;368(9535):556-557. (Pubitemid 44188864)
12. Ackerman WE, Phero JC, Theodore GT. Ineffective ventilation during conscious sedation due to chest wall rigidity after intravenous midazolam and fentanyl. Anesth Prog. 1990;37(1):46-48. (Pubitemid 20312828)
13. Burt DR. Reducing GABA receptors. Life Sci. 2003;73(14):1741-1758. (Pubitemid 36897736)
14. Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine toxicity: experience with 127 cases. J Emerg Med. 1989;7(2):157-161. (Pubitemid 19120311)
15. Gay GR, Inaba DS, Sheppard CW, Newmeyer JA. Cocaine: history, epidemiology, human pharmacology, and treatment. A perspective on a new debut for an old girl. Clin Toxicol. 1975;8(2):149-178.
16. Rosenberg J, Pentel P, Pond S, Benowitz N, Olson K. Hyperthermia associated with drug intoxication. Crit Care Med. 1986;14(11):964-969. (Pubitemid 17197748)
17. Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. 1996;335(2):128-129. (Pubitemid 26240117)
18. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406-433. (Pubitemid 40834286)
19. Hoffman RS, Kirrane BM, Marcus SM; Clenbuterol Study Investigators. A descriptive study of an outbreak of clenbuterol-containing heroin. Ann Emerg Med. 2008;52(5):548-553.
20. Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine. Ann Emerg Med. 1991;20(2):165-175.
21. Guinn MM, Bedford JA, Wilson MC. Antagonism of intravenous cocaine lethality in nonhuman primates. Clin Toxicol. 1980;16(4):499-508. (Pubitemid 10048632)
22. Derlet RW, Albertson TE, Rice P. Antagonism of cocaine, amphetamine, and methamphetamine toxicity. Pharmacol Biochem Behav. 1990;36(4):745-749. (Pubitemid 20272287)
23. Espelin DE, Done AK. Amphetamine poisoning. Effectiveness of chlorpromazine. N Engl J Med. 1968;278(25):1361-1365.
24. Kierzkowska B, Stańczyk J, Kasprzak JD. Myocardial infarction in a 17-year-old body builder using clenbuterol. Circ J. 2005;69(9):1144-1146. (Pubitemid 41603106)
25. Victor M, Brausch C. The role of abstinence in the genesis of alcoholic epilepsy. Epilepsia. 1967;8(1):1-20.
26. Yost DA. Alcohol withdrawal syndrome. Am Fam Physician. 1996;54(2):657-664., 669.
27. Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med. 1998;16(5):505-507. (Pubitemid 28385617)
28. Frascogna N. Physostigmine: is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr. 2007;19(2):201-205. (Pubitemid 46668074)
29. Gowdy JM. Stramonium intoxication: review of symptomatology in 212 cases. JAMA. 1972;221(6):585-587.
30. Longo VG. Behavioral and electroencephalographic effects of atropine and related compounds. Pharmacol Rev. 1966; 18(2):965-996.
31. O'Malley GF, Seifert S, Heard K, Daly F, Dart RC. Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med. 1999;34(2):279-281. (Pubitemid 29361880)
32. Watemberg NM, Roth KS, Alehan FK, Epstein CE. Central anticholinergic syndrome on therapeutic doses of cyproheptadine . Pediatrics. 1999;103(1):158-160. (Pubitemid 29281945)
33. Eddleston M, Dawson A, Karalliedde L, et al. Early management after self-poisoning with an organophosphorus or carbamate pesticide - a treatment protocol for junior doctors. Crit Care. 2004;8(6):R391-R397.
34. Bird SB, Gaspari RJ, Dickson EW. Early death due to severe organophosphate poisoning is a centrally mediated process. Acad Emerg Med. 2003;10(4):295-298. (Pubitemid 36437784)
35. De Bleecker JL. The intermediate syndrome in organophosphate poisoning: an overview of experimental and clinical observations. J Toxicol Clin Toxicol. 1995;33(6):683-686. (Pubitemid 26005212)
36. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
37. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148(6):705-713.
38. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003; 96(9):635-642. (Pubitemid 37063272)
39. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13(4):763-783.
40. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987;22(8):1004-1020. (Pubitemid 17095324)
41. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22(2):389-411. (Pubitemid 38388555)
42. GuzéBH, Baxter LR Jr. Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985;313(3):163-166. (Pubitemid 15047459)
43. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008;69(7):1157-1165. (Pubitemid 352031600)
44. Hammett-Stabler CA, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clin Chim Acta. 2002; 315(1-2):125-135. (Pubitemid 33145253)
45. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66-76.
46. Lindigkeit R, Boehme A, Eiserloh I, et al. Spice: a never ending story? Forensic Sci Int. 2009;191(1-3):58-63.
47. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010;198(1-3):31-38.
48. Saidinejad M, Law T, Ewald MB. Interference by carbamazepine and oxcarbazepine with serum-and urine-screening assays for tricyclic antidepressants. Pediatrics. 2007;120(3):e504-e509. (Pubitemid 47358261)
49. Caravati EM, Juenke JM, Crouch BI, Anderson KT. Quetiapine cross-reactivity with plasma tricyclic antidepressant immunoassays. Ann Pharmacother. 2005;39(9):1446-1449. (Pubitemid 41197124)
50. Hendrickson RG, Morocco AP. Quetiapine cross-reactivity among three tricyclic antidepressant immunoassays. J Toxicol Clin Toxicol. 2003;41(2):105-108. (Pubitemid 36520457)
51. Chattergoon DS, Verjee Z, Anderson M, et al. Carbamazepine interference with an immune assay for tricyclic antidepressants in plasma. J Toxicol Clin Toxicol. 1998;36(1-2):109-113. (Pubitemid 28185406)
52. Sorisky A, Watson DC. Positive diphenhydramine interference in the EMIT-st assay for tricyclic antidepressants in serum. Clin Chem. 1986;32(4):715.
53. Phillips JE, Bogema S, Fu P, et al. Signify ER drug screen test evaluation: comparison to triage drug of abuse panel plus tricyclic antidepressants. Clin Chim Acta. 2003;328(1-2):31-38. (Pubitemid 36135777)
54. McQuillen KK, Anderson AC. Osmol gaps in the pediatric population. Acad Emerg Med. 1999;6(1):27-30. (Pubitemid 29031667)
55. Kelleher SP, Raciti A, Arbeit LA. Reduced or absent serum anion gap as a marker of severe lithium carbonate intoxication. Arch Intern Med. 1986;146(9):1839-1840. (Pubitemid 16018935)
56. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2(1):162-174.
57. Ishihara K, Szerlip HM. Anion gap acidosis. Semin Nephrol. 1998;18(1):83-97. (Pubitemid 28063131)
58. Gabow PA. Disorders associated with an altered anion gap. Kidney Int. 1985;27(2):472-483. (Pubitemid 15142704)
59. Worthley LIG, Guerin M, Pain RW. For calculating osmolality, the simplest formula is the best. Anaesth Intensive Care. 1987;15(2):199-202.
60. Hoffman RS, Smilkstein MJ, Howland MA, Goldfrank LR. Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol. 1993;31(1):81-93. (Pubitemid 23063473)
61. Kruse JA, Cadnapaphornchai P. The serum osmole gap. J Crit Care. 1994;9(3):185-197. (Pubitemid 24289905)
62. Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy. 2008;28(8):984-991.
63. Curry SC, Patrick HC. Lack of evidence for a percent saturation gap in cyanide poisoning. Ann Emerg Med. 1991; 20(5):523-528.
64. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA. 1995;274(7):562-569.
65. Watson AJ, Walker JF, Tomkin GH, Finn MM, Keogh JA. Acute Wernickes encephalopathy precipitated by glucose loading. Ir J Med Sci. 1981;150(10):301-303. (Pubitemid 12214596)
66. Togay-Işikay C, Yiǧit A, Mutluer N. Wernicke's encephalopathy due to hyperemesis gravidarum: an under-recognised condition. Aust N Z J Obstet Gynaecol. 2001;41(4):453-456. (Pubitemid 33100690)
67. Nakada T, Knight RT. Alcohol and the central nervous system. Med Clin North Am. 1984;68(1):121-131. (Pubitemid 14179085)
68. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219-230.
69. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 7th ed. Foster City, CA: Biomedical Publications; 2004.
70. Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15(5):566-570. (Pubitemid 16052110)
71. Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary edema. Ann Emerg Med. 1987;16(11):1294-1296. (Pubitemid 18018393)
72. Partridge BL, Ward CF. Pulmonary edema following lowdose naloxone administration. Anesthesiology. 1986;65(6):709-710. (Pubitemid 17212501)
73. Prough DS, Roy R, Bumgarner J, Shannon G. Acute pulmonary edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology. 1984;60(5):485-486. (Pubitemid 14139855)
74. Cowan A, Geller EB, Adler MW. Classification of opioids on the basis of change in seizure threshold in rats. Science. 1979;206(4417):465-467. (Pubitemid 10241245)
75. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983;13(2):180-185. (Pubitemid 13188214)
76. Rehni AK, Singh I, Kumar M. Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gammaaminobutyric acid inhibitory pathway. Basic Clin Pharmacol Toxicol. 2008;103(3):262-266.
77. Spiller HA, Gorman SE, Villalobos D, et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol. 1997;35(4):361-364. (Pubitemid 27285824)
78. Van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105(1):51-57. (Pubitemid 44305191)
79. Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol. 2008;605 :486-491.
80. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: ipecac syrup. Clin Toxicol. 2004;42(2):133-143.
81. Vale JA, Kulig K; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol. 2004;42(7):933-943.
82. Pond SM, Lewis-Driver DJ, Williams GM, Green AC, Stevenson NW. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust. 1995; 163(7):345-349.
83. Chyka PA, Seger D, Krenzelok EP, Vale JA; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. Clin Toxicol(Phila). 2005; 43(2):61-87.
84. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen(paracetamol) overdose. J Toxicol Clin Toxicol. 1999;37(6):753-757.
85. Hoffman RS, Stringer JA, Feinberg RS, Goldfrank LR. Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate. J Toxicol Clin Toxicol. 1999;37(7):833-837. (Pubitemid 30013371)
86. Francis RC, Schefold JC, Bercker S, et al. Acute respiratory failure after aspiration of activated charcoal with recurrent deposition and release from an intrapulmonary cavern. Intensive Care Med. 2009;35(2):360-363.
87. Arnold TC, Willis BH, Xiao F, Conrad SA, Carden DL. Aspiration of activated charcoal elicits an increase in lung microvascular permeability. J Toxicol Clin Toxicol. 1999;37(1):9-16.
88. Elliott CG, Colby TV, Kelly TM, Hicks HG. Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal . Chest. 1989;96(3):672-674. (Pubitemid 19230400)
89. Menzies DG, Busuttil A, Prescott LF. Fatal pulmonary aspiration of oral activated charcoal. BMJ. 1988;297(6646):459-460.
90. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: cathartics. Clin Toxicol. 2004;42(3):243-253.
91. American academy of Clinical Toxicology; European Association of Poison Centers and Clinical Toxicologists. Position paper and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol. 1999;37(6):731-751.
92. Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther. 1989;46(3):264-271. (Pubitemid 19254758)
93. Smith SW, Ling LJ, Halstenson CE. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med. 1991;20(5):536-539.
94. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: whole bowel irrigation. Clin Toxicol. 2004;42(6):843-854.
95. Burkhart KK, Kulig KW, Rumack B. Whole-bowel irrigation as treatment for zinc sulfate overdose. Ann Emerg Med. 1990;19(10):1167-1170. (Pubitemid 20365209)
96. Mizutani T, Yamashita M, Okubo N, Tanaka M, Naito H. Efficacy of whole bowel irrigation using solutions with or without adsorbent in the removal of paraquat in dogs. Hum Exp Toxicol. 1992;11(6):495-504. (Pubitemid 23023514)
97. Tenenbein M. Whole bowel irrigation in iron poisoning. J Pediatr. 1987;111(1):142-145. (Pubitemid 17092666)
98. Traub SJ, Hoffman RS, Nelson LS. Body packing - the internal concealment of illicit drugs. N Engl J Med. 2003;349(26):2519-2526. (Pubitemid 38010078)
99. Litovitz T, Schmitz BF. Ingestion of cylindrical and button batteries: an analysis of 2382 cases. Pediatrics. 1992;89(4 pt 2):747-757.
100. Cameron RJ, Hungerford P, Dawson AH. Efficacy of charcoal hemoperfusion in massive carbamazepine poisoning. J Toxicol Clin Toxicol. 2002;40(4):507-512. (Pubitemid 34976728)
101. Huang Z, Letteri JJ, Clark WR, Ronco C, Gao D. Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury. Int J Artif Organs. 2008;31(6):525-534.
102. Mitzner SR, Stange J, Klammt S, Koball S, Hickstein H, Reisinger EC. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J. 2009;55(5):498-502.
103. Goodman JW, Goldfarb DS. The role of continuous renal replacement therapy in the treatment of poisoning. Semin Dial. 2006;19(5):402-407. (Pubitemid 44393562)
104. Vinsonneau C, Camus C, Combes A, et al Hemodiafe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet. 2006;368(9533):379-385. (Pubitemid 44108121)
105. Rabindranath K, Adams J, Macleod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev. 2007;3:CD003773.
106. Fertel BS, Nelson LS, Goldfarb DS. Extracorporeal removal techniques for the poisoned patient: a review for the intensivist. J Intensive Care Med. 2010;25(3):139-148.
107. O'Malley GF. Emergency department management of the salicylate-poisoned patient. Emerg Med Clin North Am. 2007;25(2):333-346. (Pubitemid 46669881)
108. Vermeire S, Vanbrabant P, Van Boxstael P, Sabbe M. Severity (and treatment) of chronic lithium poisoning:clinical signs or lab results as a criterion? Acta Clin Belg. 2010;65(2):127-128.
109. Jammalamadaka D, Raissi S. Ethylene glycol, methanol and isopropyl alcohol intoxication. Am J Med Sci. 2010;339(3):276-281.
110. Hall TL. Fomepizole in the treatment of ethylene glycol poisoning. CJEM. 2002;4(3):199-204.
111. Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med. 2009;360(21):2216-2223.
112. Velez LI, Shepherd G, Lee YC, Keyes DC. Ethylene glycol ingestion treated only with fomepizole. J Med Toxicol. 2007;3(3):125-128.
113. Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008;51(4):412-415., 415, e1.
114. Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42(1):1-26. (Pubitemid 38450934)
115. Bechtel LK, Haverstick DM, Holstege CP. Verapamil toxicity dysregulates the phosphatidylinositol 3-kinase pathway. Acad Emerg Med. 2008;15(4):368-374.
116. Lheureux PE, Zahir S, Gris M, Derrey AS, Penaloza A. Bench-to-bedside review:hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Crit Care. 2006;10(3):212.
117. Shepherd G, Klein-Schwartz W. High-dose insulin therapy for calcium-channel blocker overdose. Ann Pharmacother. 2005;39(5):923-930. (Pubitemid 40570672)
118. Levine MD, Boyer E. Hyperinsulinemia-euglycemia therapy: a useful tool in treating calcium channel blocker poisoning. Crit Care. 2006;10(4):149.
119. Greene SL, Gawarammana I, Wood DM, Jones AL, Dargan PI. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33(11):2019-2024. (Pubitemid 47632262)
120. Boyer EW, Duic PA, Evans A. Hyperinsulinemia/euglycemia therapy for calcium channel blocker poisoning. Pediatr Emerg Care. 2002;18(1):36-37. (Pubitemid 34174344)
121. Manavi MV. Lipid infusion as a treatment for local anesthetic toxicity:a literature review. AANA J. 2010;78(1):69-78.
122. Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia. 2006;61(8):800-801. (Pubitemid 44027411)
123. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006;105(1):217-218. (Pubitemid 44305211)
124. Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia- Amaro MF, Cwik MJ. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology. 1998;88(4):1071-1075. (Pubitemid 28193335)
125. Harvey M, Cave G. Intralipid outperforms sodium bicarbonate in a rabbit model of clomipramine toxicity. Ann Emerg Med. 2007;49(2):178-185.
126. Tebbutt S, Harvey M, Nicholson T, Cave G. Intralipid prolongs survival in a rat model of verapamil toxicity. Acad Emerg Med. 2006;13(2):134-139. (Pubitemid 43155818)
127. Bania TC, Chu J, Perez E, Su M, Hahn IH. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. Acad Emerg Med. 2007;14(2):105-111. (Pubitemid 46157192)
128. Harvey MG, Cave GR. Intralipid infusion ameliorates propranolol-induced hypotension in rabbits. J Med Toxicol. 2008;4(2):71-76.
129. Felice KL, Schumann HM. Intravenous lipid emulsion for local anesthetic toxicity: a review of the literature. J Med Toxicol. 2008;4(3):184-191.
130. American College of Medical Toxicology. Interim guidance for the use of lipid resuscitation therapy. American College of Medicial Toxicology Web site. http://www.acmt.net/cgi/page.cgi? aid=3384&-id=52&zine=show. Accessed November 26, 2010.
131. Turner-Lawrence DE, Kerns Ii W. Intravenous fat emulsion: a potential novel antidote. J Med Toxicol. 2008;4(2):109-114.
132. Smith NA. Possible side effects of Intralipid rescue therapy. Anaesthesia. 2010;65(2):210-211.
133. Leskiw U, Weinberg GL. Lipid resuscitation for local anesthetic toxicity: is it really lifesaving? Curr Opin Anaesthesiol. 2009;22(5):667-671.
134. Bebarta VS, Tanen DA, Lairet J, Dixon PS, Valtier S, Bush A. Hydroxocobalamin and sodium thiosulfate versus sodium nitrite and sodium thiosulfate in the treatment of acute cyanide toxicity in a swine(Sus scrofa) model. Ann Emerg Med. 2010;55(4):345-351.
135. DesLauriers CA, Burda AM, Wahl M. Hydroxocobalamin as a cyanide antidote. Am J Ther. 2006;13(2):161-165.
136. Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Ann Emerg Med. 2007;49(6):806-813. (Pubitemid 46778875)
137. Cyanokit [prescribing information]. Columbia, MD: Meridian Medical Technologies; Revised March, 2010.
138. Gerth K, Ehring T, Braendle M, Schelling P. Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic profile. Clin Toxicol(Phila). 2006;44(suppl 1):29-36.
139. Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med. 1994;24(1):65-67. (Pubitemid 24214622)
140. Pamidi PV, DeAbreu M, Kim D, Mansouri S. Hydroxocobalamin and cyanocobalamin interference on co-oximetry based hemoglobin measurements. Clin Chim Acta. 2009;401(1-2):63-67.
141. Lee J, Mukai D, Kreuter K, Mahon S, Tromberg B, Brenner M. Potential interference by hydroxocobalamin on cooximetry hemoglobin measurements during cyanide and smoke inhalation treatments. Ann Emerg Med. 2007;49(6):802-805. (Pubitemid 46755438)
142. Sutter M, Tereshchenko N, Rafii R, Daubert GP. Hemodialysis complications of hydroxocobalamin: a case report. J Med Toxicol. 2010;6(2):165-167.